Determination of drug-related problems according to PAIR criteria in dialysis patients: a cross-sectional study in tertiary care hospital

Aysel Pehlivanli, Sayeste Akkan Eren, Sule Sengul, Bilgen Basgut, Sehsuvar Erturk, A. Tanju Ozcelikay
{"title":"Determination of drug-related problems according to PAIR criteria in dialysis patients: a cross-sectional study in tertiary care hospital","authors":"Aysel Pehlivanli, Sayeste Akkan Eren, Sule Sengul, Bilgen Basgut, Sehsuvar Erturk, A. Tanju Ozcelikay","doi":"10.1186/s40360-024-00754-6","DOIUrl":null,"url":null,"abstract":"Dialysis patients are at high risk for drug-related problems (DRPs), which have significant consequences for their morbidity, mortality, and quality of life. Improved clinical outcomes can be achieved by preventing, identifying, and resolving these problems. This is a retrospective observational study. In this study, the PAIR instrument (Pharmacotherapy Assessment in Chronic Renal Disease) was validated for use in Turkish. Validation consisted of three stages: translation back-translation with expert panel evaluation, reliability analysis using the test-retest method, and conceptual validity with both Pharmaceutical Care Network Europe (PCNE) and PAIR used to determine DRPs prevalence. In total, 104 patients (mean ± SD age, 54.1 ± 15.8 years; 53.8% male) were included in the study. An expert panel evaluated the items in the criterion based on their intelligibility, service of purpose, differentiation, and cultural suitability during the translation stage. Content validity index (CVI) score was found to be 0.95. The reliability analysis was performed by applying the test-retest method and calculating correlation coefficient on 30 randomly selected patients one month later. Correlation coefficient (p) was found to be 0.8. To evaluate conceptual validity, 104 patients’ pharmacotherapy plans were assessed using both the PAIR and PCNE criteria. The prevalence of DRPs according to PAIR criteria (100.0%) and PCNE (73.1%) were statistically significantly different (p < 0.001). As a result, PAIR criteria can identify clinically relevant DRPs in patients with CKD and is a new, validated tool to be used in Turkey, but may not be adequate for patients receiving dialysis. Therefore, it needs to be reviewed and updated for dialysis patients.","PeriodicalId":501597,"journal":{"name":"BMC Pharmacology and Toxicology","volume":"176 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology and Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40360-024-00754-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Dialysis patients are at high risk for drug-related problems (DRPs), which have significant consequences for their morbidity, mortality, and quality of life. Improved clinical outcomes can be achieved by preventing, identifying, and resolving these problems. This is a retrospective observational study. In this study, the PAIR instrument (Pharmacotherapy Assessment in Chronic Renal Disease) was validated for use in Turkish. Validation consisted of three stages: translation back-translation with expert panel evaluation, reliability analysis using the test-retest method, and conceptual validity with both Pharmaceutical Care Network Europe (PCNE) and PAIR used to determine DRPs prevalence. In total, 104 patients (mean ± SD age, 54.1 ± 15.8 years; 53.8% male) were included in the study. An expert panel evaluated the items in the criterion based on their intelligibility, service of purpose, differentiation, and cultural suitability during the translation stage. Content validity index (CVI) score was found to be 0.95. The reliability analysis was performed by applying the test-retest method and calculating correlation coefficient on 30 randomly selected patients one month later. Correlation coefficient (p) was found to be 0.8. To evaluate conceptual validity, 104 patients’ pharmacotherapy plans were assessed using both the PAIR and PCNE criteria. The prevalence of DRPs according to PAIR criteria (100.0%) and PCNE (73.1%) were statistically significantly different (p < 0.001). As a result, PAIR criteria can identify clinically relevant DRPs in patients with CKD and is a new, validated tool to be used in Turkey, but may not be adequate for patients receiving dialysis. Therefore, it needs to be reviewed and updated for dialysis patients.
根据 PAIR 标准确定透析患者的药物相关问题:一项在三级医院进行的横断面研究
透析患者是药物相关问题 (DRP) 的高危人群,这些问题对他们的发病率、死亡率和生活质量都有重大影响。通过预防、识别和解决这些问题,可以改善临床疗效。这是一项回顾性观察研究。在这项研究中,PAIR 工具(慢性肾病药物治疗评估)在土耳其进行了验证。验证包括三个阶段:翻译与专家小组评估的反向翻译、使用测试-重复测试法进行可靠性分析,以及使用欧洲药品护理网络 (PCNE) 和 PAIR 进行概念验证,以确定 DRP 的流行程度。共有 104 名患者(平均 ± SD 年龄,54.1 ± 15.8 岁;53.8% 为男性)参与了研究。在翻译阶段,专家小组根据可理解性、服务目的、区分度和文化适宜性对标准中的项目进行了评估。结果发现,内容效度指数(CVI)为 0.95。一个月后,对随机抽取的 30 名患者采用重测法进行了信度分析,并计算了相关系数。相关系数(p)为 0.8。为了评估概念有效性,研究人员使用 PAIR 和 PCNE 标准对 104 名患者的药物治疗计划进行了评估。根据 PAIR 标准(100.0%)和 PCNE 标准(73.1%),DRP 的发生率在统计学上有显著差异(p < 0.001)。因此,PAIR 标准可识别慢性肾脏病患者中与临床相关的 DRP,是一种可在土耳其使用的经过验证的新工具,但对于接受透析的患者可能并不适用。因此,需要针对透析患者对该标准进行审查和更新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信